{"name":"ACADIA Pharmaceuticals Inc.","slug":"acadia-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":726437000,"revenueGrowth":214.4,"grossMargin":0,"rdSpend":328802000,"netIncome":391000000,"cash":1564195000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ACP-211","genericName":"ACP-211","slug":"acp-211","indication":"Treatment of excessive daytime sleepiness in patients with narcolepsy","status":"phase_2"},{"name":"ACP-104","genericName":"ACP-104","slug":"acp-104","indication":"Excessive daytime sleepiness in patients with narcolepsy or other conditions","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ACP-204","genericName":"ACP-204","slug":"acp-204","indication":"Cognitive impairment associated with schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"ACP-211","genericName":"ACP-211","slug":"acp-211","phase":"phase_2","mechanism":"ACP-211 is a selective histamine H3 receptor inverse agonist.","indications":["Treatment of excessive daytime sleepiness in patients with narcolepsy"],"catalyst":""},{"name":"ACP-104","genericName":"ACP-104","slug":"acp-104","phase":"phase_2","mechanism":"ACP-104 is a selective histamine H3 receptor inverse agonist.","indications":["Excessive daytime sleepiness in patients with narcolepsy or other conditions"],"catalyst":""},{"name":"ACP-204","genericName":"ACP-204","slug":"acp-204","phase":"phase_3","mechanism":"ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms.","indications":["Cognitive impairment associated with schizophrenia","Negative symptoms of schizophrenia","Psychosis in Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOM3U4R093bkR4SDRyM3F1UU1FZkR6NzJQWVVvNHJIMEZ4RlZkQnZWZVZOSVZfVFE2YkJiUnRlbm9JZE9yd2NZWjMza0xrMmtaYTBvVlFIUXFibGtTMWNTTkVGbjZHZGhKSWNWTHowVlpEQ0Zia0FfUDE1aGlsS04yQWJzT29xeXRNOGk5YVlMTlVrM09L?oc=5","date":"2026-03-25","type":"pipeline","source":"Seeking Alpha","summary":"Acadia Pharma upgraded at BofA following stock pullback - Seeking Alpha","headline":"Acadia Pharma upgraded at BofA following stock pullback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPc2Y0b3VXQkJScUo0RTU1bG5vWDZfT2dNdFhDcXhiZTdZVGlVR1BScEtBZVdaMFhJcDBGR1FuWEJTTDJBTzFocDdZdk0zSXU3d19OT1lJNkxfc2ZMc3RvdG9hVllqaU9CaTlKS2ljdmFRcUJfbTM4WUQ0bzBBUUFFZWRsX2VZREpoYWdTTE9fRTc4QWlZWEs4d2JBMUJmSFRLX3NzTkMyS0Q3bm5ScFl1OGk5UmpxbGxXTHJLZlR0RTI?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Watch Acadia’s fireside chat at Stifel’s 2026 Virtual CNS Forum - Stock Titan","headline":"Watch Acadia’s fireside chat at Stifel’s 2026 Virtual CNS Forum","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPSHJ0eXJETzdiWWY0cld1S0tXRU9jVXgycS0td2dxWTNjbEtVX3NsWWxlMGR3T1ZKYlJPaGtYdkRFTlhWYTFRLV9lemUzZUJHVXVhQm9HOFN2Q2cya3FnZ3RSbUtsd0JZMnZiYUMxc291eXUwWUQ1MVRyd1J1OGpUOWVtMjFoZlNhRWxxbXB5QWFpenA0bUJHOS1GRWU1cm9MU0JQX21BWGJFTGNIZHBiMlVlN19QNFVDNVE?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"EU advisers reject Rett syndrome drug, maker pushes for second review - Stock Titan","headline":"EU advisers reject Rett syndrome drug, maker pushes for second review","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ1J4c2ZjcGtWcHBpR0xLckljLWF3eFpDRVBQV3RDbUVIbjdCMXBZelQ3U2x3c0FPMmdrX1VueC1TUFNTbXZNbU4xdTBwaFptT3hGaHJoU1ktV1dWMWhmeC15T29UWXZPaEJFRGI0cTlic0tUbFZwYUZjM3Q5WkpNaEJiYTlTbHY3bEU1X2FTMEtELTNESFVXQlRrX0paWEJacU5RWUZ2ejBIVGo4M2FoVUxvTmNZRlhIRF9kTw?oc=5","date":"2026-02-03","type":"earnings","source":"TradingView","summary":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView","headline":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQSV9nUVFZQl9uY0tnOGRjVmktUFZ4RlgtSVhhdVB2NEJhOTBNU1BGUVJLMUdNcVZsdlFsTXc5T19ZTVFMb3pLTi03dElHQlZXWldsYlpWUVp2THRKdWhRQmdhR1VibGdRWDR6YllFQjhpa3NjVjNvV2FhajFvbVhXdGdGb2JmaHpueHl2QTV5cTJsb28?oc=5","date":"2026-01-08","type":"pipeline","source":"The Pharma Letter","summary":"Acadia drops development of carbetocin in PWS - The Pharma Letter","headline":"Acadia drops development of carbetocin in PWS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQVGRyTzZGdU5wX1pGV2RPanZCa2s2ZjhhSTU1c2hMYkszVGNxdFItVVZRY19HUy02ZlpaVlRmWC15eWc4ek5XQnotYmNZN2ZqcV9kaUVIbWZvSXd0UDFERGsxM3l1LUxseXJwNHQ3T2EzUUlILVRsbDJBd0xoTnhac2lXWVZYaFUwSDJ3bXNaSkNCMmtrWHFEbFFQdmxoRWZQcTJTZDluZ3dJSW5FNFJz?oc=5","date":"2025-10-30","type":"pipeline","source":"The Business Journals","summary":"Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus - The Business Journals","headline":"Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNLXJ1REQxQWtscDdzY3FHMEtQcFZpaW9DZHU5dWxBeVFwYTB4RmJJX2gtbmNzemtaTURJWU5RUGY4b1lrdnZ5aTFyWjVwMG54SUxxZlpmQlJxTVRpS3BvWk1NckVLM0RkeUhiQUE4d2t3eHk1U0F6bjFpMHpaM3plbUVrRndjUjgtSkhOVC14S2dfYTBXZE9oclpXTGZ1bXhwTTBlOXVXZ0NZTDRJLVA0Ni0xanJJVFVpMWpGYmJKR0JoMjB0SFNrVHp5OUlhSTlkY3NrZmY3VE5zUk1FZEhHZA?oc=5","date":"2025-10-15","type":"earnings","source":"Business Wire","summary":"Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire","headline":"Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPc1J3eUUtV1JWM1RDWXNzY2Q5dXNiT0pHc1FUZDc5V2JYSVNiTHhNU3VCVUszZlprV3BHbXl5c01nY0R1MTl5VXZRNVljdEh2Vi1oLUtuX0NHekRrOUM4SWFZRFM1NGJfSWROc0pWdDZqN0dDWGI3NGFoUkdtY1VrbWVPSXB1Ylda?oc=5","date":"2025-09-24","type":"pipeline","source":"Investor's Business Daily","summary":"Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily","headline":"Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPX0tJOGt1eWNmcTc3dEdmY0ZwaGpNNHhzRVBIazhjV3YzWDJjNzNJZy1NYXFSWVItQVlVQ0tfdUN1TkZoMXB3cG9hUm5CWTFfRUZkbS1xVDNEbW5YYXpuNmdaSEhCVG54NkY3aDNzVHQ4elhZakFaaVpfRFpQeFQ4ZjVuVkJZY2dEX1FFY3hrcmRXWk94VlRLaUk4X0g5QVVfQXNTamtON1dpV2NIMTZZVURlS0U?oc=5","date":"2025-09-24","type":"trial","source":"Fierce Pharma","summary":"Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno - Fierce Pharma","headline":"Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNMThHUTZmTVllSi1BWGlkRzQzNUt4TWFuMUhVOEdrTXRoX1lDRkp4Y3BlN01uNFQ3NzNVOHpKdGQ5bEJ3YjJTWFY2LVowb3kxX29fRGNsd2ZhVzRlUzZaN0hJaXFHRlRjTHltQ1dfV29JN2xqaEJBNXRHTGVRTEQwTkR2X3NrUXVZZ2JaeQ?oc=5","date":"2025-09-24","type":"pipeline","source":"Yahoo Finance","summary":"Lithium Americas, Oracle, Acadia Pharma: Trending Tickers - Yahoo Finance","headline":"Lithium Americas, Oracle, Acadia Pharma: Trending Tickers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPVkh2UXJGNklQYjlqZGhHWWRLUUVJWHA1d1Y0Uzl6cHVUcUxXcWU1OTBmal9PM1dreDROU0NxYW1MNGVIX1NHLU9Ub0RJN0pnWXJrWUVkN1pmUWptN3V4LTBPWVdGXzZkUzRWTVhmRTBpUWY3cjBjZk1iaEtWakIxQlJ4dmwyTTZBWWdBRjBoZjA3ZkdSVEY4QVM5NVV3Smx3ekl0UlJn?oc=5","date":"2025-07-02","type":"deal","source":"BioPharma Dive","summary":"Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline - BioPharma Dive","headline":"Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOR0ZEN29ybHNCZ1h6bjN1X2Y0aV9aNG9RRk1ZdGNmdGJKYjVVNlJNSFd4U1pMSURaZU9pbzhlYVptWjZHdE4xbWlLbTVlNkhhRm14LVcwTUk5VmVlMl9pS1ZDWGFkQjdRNlVNaG9zOXJad3Vhd1JPSWR2ZkdyYXBEc1c4RXJ4U0x3dGJCRTNYVUpCb0wyVUNaUTJ0dk5uMDJJOHVVWHFuREFiM1FqMkM0SUY3QVVyQzl1eEJIWXJoVk84YUluU3E0a01BYTBqNGJNU19F?oc=5","date":"2025-06-09","type":"patent","source":"Reuters","summary":"US appeals court confirms patent validity of Acadia's Parkinson's drug - Reuters","headline":"US appeals court confirms patent validity of Acadia's Parkinson's drug","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":726437000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":726437000,"period":"2023-12-31"},{"value":231041000,"period":"2023-12-31"},{"value":211699000,"period":"2023-09-30"},{"value":165235000,"period":"2023-06-30"},{"value":118462000,"period":"2023-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":328802000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":391000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1564195000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}